Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher`s disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Website: lixte.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -7.0% (LTM)

Entry Point: Share price is 377.2% higher than minimum and 72.9% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: LIXT
Share price, USD:  (0.0%)3.41
year average price 3.02  


year start price 2.46 2025-02-08

min close price 0.71 2025-06-27

max close price 6.01 2025-09-12

current price 3.41 2026-02-07
Common stocks: 16 649 510

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 57
Net Debt ($m): -4
EV (Enterprise Value): 53
Price to Book: 11.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-21globenewswire.com

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

2025-12-03accessnewswire.com

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

2025-09-15accessnewswire.com

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

2025-09-10globenewswire.com

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

2025-09-05newsfilecorp.com

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

2025-08-14globenewswire.com

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2025-08-13globenewswire.com

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

2025-07-09globenewswire.com

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

2025-07-09globenewswire.com

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

2025-07-08globenewswire.com

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-09 2023-08-09 2023-05-10 2022-11-08 2022-08-10
acceptedDate 2025-11-12 16:26:01 2025-08-07 08:31:07 2025-03-24 08:30:38 2024-11-12 16:50:35 2024-08-08 16:06:29 2024-05-09 08:30:49 2024-03-19 08:30:54 2023-11-09 17:16:22 2023-08-09 08:30:41 2023-05-10 08:30:30 2023-03-29 08:30:42 2022-11-08 08:30:31 2022-08-10 08:30:52 2022-03-21 08:01:01 2021-03-26 08:00:54
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
grossProfit 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 50 696 60 648 726 232 361 630 210 708 119 064 898 100 132 487 427 457 189 085 1M 272 388 164 810 2M 1M
generalAndAdministrativeExpenses 2M 714 161 3M 621 627 798 448 847 815 4M 534 013 862 571 1M 5M 1M 1M 5M 2M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 714 161 3M 621 627 798 448 847 815 4M 534 013 862 571 1M 5M 1M 1M 5M 2M
otherExpenses 0 0 0 0 0 0 0 0 0 0 0 0 269 281 0 -0
operatingExpenses 2M 774 809 4M 983 257 1M 966 879 5M 132 487 2M 1M 6M 1M 2M 7M 3M
costAndExpenses 2M 774 809 4M 983 257 1M 966 879 5M 1M 2M 1M 6M 1M 2M 7M 3M
interestIncome 4430 365 7048 1437 2233 2859 1253 5809 2714 5015 11 195 3911 191 626 5232
interestExpense 457 1810 0 1049 4154 7186 0 -279 1948 3861 8875 2119 627 7414 3674
depreciationAndAmortization 0 0 0 -1724 -4 966 879 0 1024.181 2714 5015 0 3911 0 0 3M
ebitda -2M -773 863 -4M -984 981 -1M -966 880 -5M -1M -2M -1M -6M -1M -2M -7M 0
ebitdaratio 0 0 0 0 0 0 0 0 0 0
operatingIncome -2M -774 809 -4M -983 257 -1M -966 880 -5M -1M -2M -1M -6M -1M -2M -7M -3M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -229 411 -864 -13 176 -2773 -1763 -4442 3207 5421 877 2488 -1054 492 -294 -7951 1558
incomeBeforeTax -2M -775 673 -4M -986 030 -1M -971 322 -5M -1M -2M -1M -6M -1M -2M -7M -3M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 -966 879 0 -1024.181 -766 1373 0 -2611 0 0 0
netIncome -2M -775 673 -4M -986 030 -1M -971 322 -5M -1M -2M -1M -6M -1M -2M -7M -3M
netIncomeRatio 0 0 0 0 0 0 0 0 0 0
eps -0.33 -0.29 -1.59 -0.44 -0.45 -0.43 -2.66 -0.49 -1 -0.082 -4 -0.089 -0.1 -5 -2.89
epsdiluted -0.33 -0.29 -0.44 -0.45 -0.43 -0.49 -1 -0.082 -0.089 -0.1
weightedAverageShsOut 6M 3M 2M 2M 2M 2M 2M 2M 2M 17M 2M 17M 16M 1M 1M
weightedAverageShsOutDil 6M 3M 2M 2M 2M 2M 2M 2M 2M 17M 2M 17M 16M 1M 1M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-19 2023-03-29 2022-03-21 2021-03-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 7048 1253 2320 -6788 1558
ebit -4M -5M -6M -7M -3M
nonOperatingIncomeExcludingInterest -3645 -19 440 -7821 537 0
netIncomeFromContinuingOperations -4M -5M -6M -7M -3M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -4M -5M -6M -7M -3M
epsDiluted -1.59 -2.66 -4 -5 -2.89

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-09 2023-08-09 2023-05-10 2022-11-08 2022-08-10
acceptedDate 2025-11-12 16:26:01 2025-08-07 08:31:07 2025-03-24 08:30:38 2024-11-12 16:50:35 2024-08-08 16:06:29 2024-05-09 08:30:49 2024-03-19 08:30:54 2023-11-09 17:16:22 2023-08-09 08:30:41 2023-05-10 08:30:30 2023-03-29 08:30:42 2022-11-08 08:30:31 2022-08-10 08:30:52 2022-03-21 08:01:01 2021-03-26 08:00:54
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 3M 887 212 1M 2M 3M 3M 4M 5M 3M 4M 5M 7M 8M 5M 5M
shortTermInvestments 2M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 5M 887 212 1M 2M 3M 3M 4M 5M 3M 4M 5M 7M 8M 5M 5M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 91 329 102 540 -106 551 51 337 72 382 96 924 0 27 840 49 563 56 099 0 257 628 288 034 150 241 15 000
totalCurrentAssets 5M 989 752 1M 2M 3M 4M 4M 5M 3M 4M 6M 7M 8M 5M 5M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 198 826 106 551 6928 0 78 015 0 78 014 78 015 0 0 0 0 0 76 898
totalNonCurrentAssets 0 198 826 106 551 6928 0 78 015 0 78 014 78 015 0 0 0 0 0 76 898
otherAssets 0 0 0 0 0 1 0 -78 014 -78 015 0 0 0 0 0 -76 898
totalAssets 5M 1M 1M 2M 3M 4M 4M 5M 3M 4M 6M 7M 8M 5M 5M
accountPayables 235 900 92 149 83 206 72 859 131 404 246 687 120 508 221 171 366 528 0 183 752 307 398 0 193 465 190 292
shortTermDebt 0 0 0 0 0 -462 836 0 -221 171 -366 528 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 235 155 256 147 235 078 0 290 061 216 149 157 100 90 565 36 086 26 356 165 022 100 930 158 832 0 15 765
otherCurrentLiabilities 50 367 188 826 0 256 097 0 462 836 0 221 171 366 528 223 631 0 0 372 708 76 961 0
totalCurrentLiabilities 521 422 537 122 318 284 328 956 421 465 462 836 313 858 311 736 402 614 249 987 395 756 408 328 531 540 302 926 216 524
longTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 26 356 0 -408 328 0 -0 0
totalNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 26 356 0 408 328 0 -0 0
otherLiabilities 0 0 0 0 0 0 0 0 0 -26 356 0 -408 328 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 521 422 537 122 318 284 328 956 421 465 462 836 313 858 311 736 402 614 249 987 395 756 408 328 531 540 302 926 216 524
preferredStock 3M 0 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M
commonStock 570 276 225 225 225 225 225 225 166 1665 166 1664 1664 1374 1240
retainedEarnings -56M -54M -52M -51M -50M -49M -48M -47M -46M -45M -43M -42M -40M -37M -30M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -225 0 -225 -166 0 0 0 0 0 0
othertotalStockholdersEquity 58M 54M 49M 49M 49M 49M 46M 45M 45M 44M
totalStockholdersEquity 5M 651 456 827 219 1M 2M 3M 4M 5M 3M 4M 5M 6M 7M 5M 5M
totalEquity 5M 651 456 827 219 1M 2M 3M 4M 5M 3M 4M 5M 6M 7M 5M 5M
totalLiabilitiesAndStockholdersEquity 5M 1M 2M 3M 4M 5M 3M 4M 7M 8M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 5M 1M 1M 2M 3M 4M 4M 5M 3M 4M 6M 7M 8M 5M 5M
totalInvestments 2M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netDebt -3M -887 212 -1M -2M -3M -3M -4M -5M -3M -4M -5M -7M -8M -5M -5M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-19 2023-03-29 2022-03-21 2021-03-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 106 551 105 132 207 591 119 278 144 209
totalPayables 83 206 156 758 230 734 193 465 190 292
otherPayables 0 36 250 46 982 0 0
accruedExpenses 0 0 0 32 500 10 467
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 49M 49M 45M 38M 32M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT LIXT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-09 2023-08-09 2023-05-10 2022-11-08 2022-08-10
acceptedDate 2025-11-12 16:26:01 2025-08-07 08:31:07 2025-03-24 08:30:38 2024-11-12 16:50:35 2024-08-08 16:06:29 2024-05-09 08:30:49 2024-03-19 08:30:54 2023-11-09 17:16:22 2023-08-09 08:30:41 2023-05-10 08:30:30 2023-03-29 08:30:42 2022-11-08 08:30:31 2022-08-10 08:30:52 2022-03-21 08:01:01 2021-03-26 08:00:54
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -2M -775 673 -4M -986 030 -1M -971 322 -5M -1M -2M -1M -6M -1M -2M -7M -3M
depreciationAndAmortization 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 821 322 267 999 418 422 0 130 691 102 927 773 203 112 106 280 060 276 980 2M 396 883 424 094 3M 1M
changeInWorkingCapital 49 437 20 189 3007 -140 357 61 187 79 170 20 561 -37 735 212 911 -180 690 154 758 -92 806 -72 050 -13 441 -117 881
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 367
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 59 218 -20 327 -73 552 0 -115 283 89 929 0 -145 357 142 897 -6133 2318 81 433 0 35 673 46 743
otherWorkingCapital -9781 40 516 76 559 -140 357 176 470 -10 759 20 561 107 622 70 014 -174 557 152 440 -174 239 -116 271 -49 114 -178 991
otherNonCashItems 182 887 0 0 168 792 0 12 998 0 257 463 0 0 0 0 0 0 0
netCashProvidedByOperatingActivities -926 752 -487 485 -3M -957 595 -819 041 -789 225 -4M -944 389 -1M -1M -5M -1M -1M -4M -2M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 5M 0 0 0
purchasesOfInvestments -3M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -3M 0 0 0 0 0 0 0 5M 0
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 6M -10000 0 0 0 3M 0 0 0 5M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 0 41 0 6281 5M 10 906
netCashUsedProvidedByFinancingActivities 6M -10000 0 0 0 3M 0 6281 5M 5M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 2M -497 485 -3M -957 595 -819 041 -789 225 -1M 2M -1M -1M 529 647 -1M 4M -245 521 2M
cashAtEndOfPeriod 3M 887 212 1M 2M 3M 3M 4M 5M 3M 4M 5M 7M 8M 5M 5M
cashAtBeginningOfPeriod 887 212 1M 4M 3M 3M 4M 5M 3M 4M 5M 5M 8M 4M 5M 3M
operatingCashFlow -926 752 -487 485 -3M -957 595 -819 041 -789 225 -4M -944 389 -1M -1M -5M -1M -1M -4M -2M
capitalExpenditure 2 5 -4 0 0 0 0 0 0 0 -3 0 0 0 0
freeCashFlow -926 750 -487 480 -3M -957 595 -819 041 -789 225 -4M -944 389 -1M -1M -5M -1M -1M -4M -2M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-19 2023-03-29 2022-03-21 2021-03-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities 0 0 0 0 0
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 3M 5M 4M 5M
netCommonStockIssuance 0 3M 5M 4M 5M
commonStockIssuance 0 3M 5M 4M 5M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 6322 0 207 633 0
netCashProvidedByFinancingActivities 0 3M 5M 4M 5M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 16 233 0 7414 3674

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-12-31 16:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q3
SEC form 8
2025-12-31 16:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q3
SEC form 8
2025-12-23 21:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q3
SEC form 8
2025-12-23 21:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q3
SEC form 8
2025-12-23 21:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q3
SEC form 8
2025-12-23 21:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q3
SEC form 8
2025-12-11 19:51 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q3
SEC form 10
2025-11-12 16:26 ET
Lixte Biotechnology Holdings, Inc. reported for 2025 q3
SEC form 8
2025-09-11 17:28 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-09-11 17:28 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-08-18 22:04 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-08-18 22:04 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-08-13 22:30 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-08-13 22:30 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 10
2025-08-07 12:31 ET
Lixte Biotechnology Holdings, Inc. reported for 2025 q2
SEC form 8
2025-07-16 20:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-16 20:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-11 12:45 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-11 12:45 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-08 21:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-08 21:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-08 21:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-08 21:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-08 21:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 8
2025-07-08 21:29 ET
Lixte Biotechnology Holdings, Inc. published news for 2025 q2
SEC form 10
2025-05-12 12:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2025 q1
SEC form 10
2025-05-12 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2025 q1
SEC form 8
2025-03-31 20:26 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-03-31 20:26 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-03-27 21:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-03-27 21:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 10
2025-03-24 12:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2024 q4
SEC form 10
2025-03-24 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2024 q4
SEC form 8
2025-03-14 14:25 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-03-14 14:25 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-03-11 12:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-03-11 12:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-02-25 21:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 8
2025-02-25 21:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2024 q4
SEC form 10
2024-11-12 16:50 ET
Lixte Biotechnology Holdings, Inc. reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2024 q3
SEC form 10
2024-08-08 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2024 q1
SEC form 10
2024-03-19 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q4
SEC form 10
2023-11-09 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q3
SEC form 10
2023-08-09 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q2
SEC form 6
2023-07-21 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q2
SEC form 6
2023-07-20 11:45 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q2
SEC form 6
2023-06-26 06:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 10
2023-05-10 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q1
SEC form 6
2023-05-09 18:57 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 6
2023-04-25 15:48 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 6
2023-04-11 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 6
2023-04-05 09:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 10
2023-03-29 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q4
SEC form 6
2023-03-24 17:14 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q4
SEC form 6
2023-02-15 15:50 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q4
SEC form 6
2023-02-09 21:21 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q4
SEC form 6
2022-12-23 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-12-06 17:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-12-02 16:31 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-11-10 16:10 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 10
2022-11-08 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q3
SEC form 6
2022-10-18 13:14 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-10-11 06:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-08-26 14:48 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q2
SEC form 6
2022-08-15 18:34 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q2
SEC form 10
2022-08-10 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q2
SEC form 6
2022-06-24 17:10 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-06-23 08:09 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-06-16 18:47 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-05-13 13:40 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 10
2022-05-11 08:15 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q1
SEC form 6
2022-04-14 20:20 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-03-23 12:54 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q4
SEC form 10
2022-03-21 08:01 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q4
SEC form 10
2022-03-21 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q4
SEC form 10
2021-11-10 08:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q3
SEC form 6
2021-10-13 10:01 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q3
SEC form 6
2021-09-20 17:21 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 10
2021-08-10 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 6
2021-07-09 17:30 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 6
2021-06-03 15:21 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-05-24 19:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-05-14 14:42 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-05-13 14:12 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 10
2021-05-12 09:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-04-13 16:52 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 10
2021-03-26 08:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q4
SEC form 6
2021-03-02 16:55 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q4
SEC form 6
2021-01-22 14:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q4
SEC form 6
2020-12-01 20:51 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q3
SEC form 6
2020-11-27 16:43 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q3
SEC form 10
2020-11-10 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q3